Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cyclacel Pharmaceuticals Q2 2024 GAAP EPS $(0.72) Beats $(1.44) Estimate, Sales $4.00K Miss $30.00K Estimate

Author: Benzinga Newsdesk | August 14, 2024 04:20pm
Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(1.44) by 50 percent. The company reported quarterly sales of $4.00 thousand which missed the analyst consensus estimate of $30.00 thousand by 86.67 percent. This is a 98.93 percent decrease over sales of $373.00 thousand the same period last year.

Posted In: CYCC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist